Ovid Therapeutics Inc. (NASDAQ: OVID) announced the appointment of Anna Greka, M.D., Ph.D., to its board of directors, effective June 15, 2026.

Greka serves as a core institute member at the Broad Institute of MIT and Harvard and is a professor of medicine at Harvard Medical School and Mass General Brigham. She currently leads the Ladders to Cures Scientific Accelerator, an organization focused on translating fundamental discoveries into therapies.

The physician-scientist has founded and advised multiple biotechnology companies, including Goldfinch Bio, which was acquired by Bristol Myers Squibb, and a company recently acquired by AstraZeneca. She holds over 25 years of experience in advancing biological discoveries into clinical-stage assets.

Greka earned her M.D. and Ph.D. in neurobiology from Harvard Medical School and MIT. Her scientific work has received recognition including the Presidential Early Career Award for Scientists and Engineers and election as president of the American Society for Clinical Investigation.

She will chair Ovid's newly formed Science and Technology Committee and serve on the Compensation Committee, both positions beginning June 15, 2026.

Ovid Therapeutics develops small molecule medicines for neurological and neuropsychiatric disorders. The company is developing OV329 for treatment-resistant focal onset seizures and developmental and epileptic encephalopathies, and OV4071 within a library of compounds that directly activate the KCC2 transporter for central nervous system disorders.